stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Free cash flow margin
Fortrea Holdings Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 6.41%, up 3.2 percentage points from fiscal 2025 (3.24%). Over the past ten years it has ranged from 1.01% (fiscal 2022) to 8.82% (fiscal 2024); the current reading is higher than 33% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 3.24% | (5.58) |
| FY2024 | 8.82% | 4.01 |
| FY2023 | 4.81% | 3.80 |
| FY2022 | 1.01% | (3.69) |
| FY2021 | 4.70% | (3.09) |
| FY2020 | 7.79% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 32.7% |
| SRPT Sarepta Therapeutics, Inc. compare | 9.02% |
| FTRE Fortrea Holdings Inc. | 6.41% |
| IMNM Immunome, Inc. compare | 0.00% |
| REPL Replimune Group, Inc. compare | 0.00% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| BHVN Biohaven Ltd. compare | 0.00% |
| VIR Vir Biotechnology, Inc. compare | −46.9% |
| ZYME Zymeworks Inc. compare | −324.7% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue